Overall rank by patents
#4,902
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
NGM Biopharmaceuticals, Inc.
USPTO PatentsView assignee record - 71 granted patents across 7 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
71
Total patents granted
7
CPC technology areas
40.5
Avg claims per patent
+15%
5-year filing velocity
The verdict
NGM holds 71 US patents across 7 technology areas, rank #4,902 of 50,000 tracked assignees.
- #4,902
- of 50,000 US assignees by volume
- Top 29%
- by Innovation Score (43.1/100)
- 40.5
- avg claims per patent
- +15%
- filing velocity, last 5 yrs
Portfolio overview
NGM Biopharmaceuticals, Inc. has been granted 71 US utility patents between 2015 and 2025, placing NGM Biopharmaceuticals, Inc. at rank #4,902 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 40.5 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, NGM Biopharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, NGM sits between Matthews International Corporation (71 patents, rank #4,898) and PME IP PTY Ltd (71 patents, rank #4,906) - the closest US assignees by grant volume. The composite Innovation Score of 43.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 38 grants, compared with 33 in the 2015–2019 window, a +15% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. NGM Biopharmaceuticals, Inc.'s 40.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark NGM Biopharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at NGM's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Matthews Internat…
Matthews International Corporation
71 patents
- Mcalister
McAlister Technologies, LLC
71 patents
- National Universi…
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
71 patents
- National Universi…
NATIONAL UNIVERSITY OF DEFENSE TECHNOLOGY
71 patents
- Nuvera Fuel Cells
Nuvera Fuel Cells, LLC
71 patents
- OHIO State Univer…
OHIO STATE UNIVERSITY
71 patents
- Omeros
Omeros Corporation
71 patents
- PME IP PTY
PME IP PTY LTD
71 patents
- NGM Biopharmaceut… ◀
NGM Biopharmaceuticals, Inc.
71 patents
What this shows NGM holds 71 patents at rank #4,902, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near NGM
By rank, the assignees closest to #4,902 in granted patent volume.
- Matthews International Corporation #4,898 · 71 patents
- Mcalister Technologies, Llc #4,899 · 71 patents
- National University Corporation Gunma University #4,900 · 71 patents
- National University OF Defense Technology #4,901 · 71 patents
- Nuvera Fuel Cells, Llc #4,903 · 71 patents
- OHIO State University #4,904 · 71 patents
- Omeros Corporation #4,905 · 71 patents
- PME IP PTY Ltd #4,906 · 71 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in NGM's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
NGM's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
43 Top 29% higher than 71% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 4.2% |
| 2016 | 2 | 2.8% |
| 2017 | 8 | 11.3% |
| 2018 | 11 | 15.5% |
| 2019 | 9 | 12.7% |
| 2020 | 10 | 14.1% |
| 2021 | 8 | 11.3% |
| 2022 | 4 | 5.6% |
| 2023 | 10 | 14.1% |
| 2024 | 2 | 2.8% |
| 2025 | 4 | 5.6% |
Which technologies does NGM Biopharmaceuticals, Inc. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Growing
Frequently Asked Questions
How many patents does NGM Biopharmaceuticals, Inc. hold?
NGM Biopharmaceuticals, Inc. holds 71 US granted patents filed between 2015 and 2025, spanning 7 technology areas.
What is NGM Biopharmaceuticals, Inc.'s Innovation Score?
NGM Biopharmaceuticals, Inc. has an Innovation Score of 43.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does NGM Biopharmaceuticals, Inc. focus on?
NGM Biopharmaceuticals, Inc.'s top technology area is C07K (PEPTIDES) with 68 patents. The company has filed patents in 7 CPC subclasses total.
Is NGM Biopharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
NGM Biopharmaceuticals, Inc.'s recent filing velocity is +15% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for NGM Biopharmaceuticals, Inc.'s patents?
NGM Biopharmaceuticals, Inc.'s patents average 40.5 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the NGM Biopharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
NGM's 71 grants land it in the top 29% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - NGM ranks #4,902 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.